Skip to main content
SpringerLink
Log in

Salmeterol and its relationship to treatment with inhaled corticosteroids

  • Conference paper
Treatment of Asthma: The long-acting beta-2-agonists

  • 185 Accesses

Summary

In the context of control of asthma symptoms β2-agonists have a major role. The long-acting inhaled β2-agonists, such as salmeterol, would appear to be extremely valuable, not only in control of night-time and exercise related symptoms but also as an addition to inhaled steroids in patients who continue to have symptoms. In this last context the addition of salmeterol is significantly more effective than doubling or more than doubling the dose of inhaled steroid.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sears MR, Taylor DR, Print CG, et al (1990) Regular inhaled 13-agonist treatment in bronchial asthma. Lancet 336: 1391–6

    Article  PubMed  CAS  Google Scholar 

  2. van Schayck CP, Dompeling E, van Herwaarden CLA, et al (1991) Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. Brit Med J 303: 1426–31

    Article  PubMed  Google Scholar 

  3. Spitzer WO, Suissa S, Ernst P, et al (1992) The use of 13-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501–6

    Article  PubMed  CAS  Google Scholar 

  4. Trembath PW, Greenacre JK, Anderson M, et al (1979) Comparison of four week’s treatment with fenoterol and terbutaline aerosols in adult asthmatics. A double blind crossover study. J Allergy Clin Immunol 63: 395–400

    Google Scholar 

  5. Harvey JE, Tattersfield AE (1982) Airway response to salbutamol: effect of regular salbutamol inhalation in normal, atopic and asthmatic subjects. Thorax 37: 280–7

    Article  PubMed  CAS  Google Scholar 

  6. Wahedna I, Wong CS, Wisniewski AFZ, et al (1993) Asthma control during and after cessation of regular beta2-agonist treatment. Am Rev Respir Dis 148: 707–12

    Article  PubMed  CAS  Google Scholar 

  7. Bel EH, Zwinderman AH, Timmers MC, et al (1991) The protective effect of a p2-agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 46: 9–14

    Article  PubMed  CAS  Google Scholar 

  8. Gongora HC, Wisniewski AFZ, Tattersfield AE (1991) A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway activity in asthmatic subjects. Am Rev Respir Dis 144: 626–9

    Article  PubMed  CAS  Google Scholar 

  9. Vathenen AS, Knox AJ, Higgins BG, et al (1988) Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet i: 544–8

    Google Scholar 

  10. Kraan J, Kroeter GH, van der Mark TW, et al (1985) Changes in bronchial hyperreactivity induced by 4 weeks of treatment with anti-asthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 76: 628–36

    Article  PubMed  CAS  Google Scholar 

  11. Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ (1987) Effect of long term treatment with inhaled corticosteroids and 0-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 79: 653–9

    Article  PubMed  CAS  Google Scholar 

  12. Cockroft DW, McPharland CP, Britto SA, et al (1993) Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 342: 833–7

    Article  Google Scholar 

  13. Cockroft DW, O’Byrne PM, Swystun VA, et al (1995) Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 96: 44–9

    Article  Google Scholar 

  14. Speizer FE, Doll R, Heaf P (1968) Observations on recent increase in mortality from asthma. Br Med J 1: 335–9

    Article  PubMed  CAS  Google Scholar 

  15. Speizer FE, Doll R (1968) A century of asthma deaths in young people. Br Med J 3: 245–6

    Article  PubMed  CAS  Google Scholar 

  16. Gandevia B (1968) The changing pattern of mortality from asthma in Australia. Med J Aust 1: 747–52 and 884–91

    PubMed  CAS  Google Scholar 

  17. Inman WHW, Adelstein AM (1969) Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet ii: 279–85

    Article  Google Scholar 

  18. Stolley P (1972) Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 105: 883–90

    PubMed  CAS  Google Scholar 

  19. Crane J, Pearce N, Flatt A, et al (1989) Prescribed fenoterol and death from asthma in New Zealand, 1981–1983: case control study. Lancet i: 279–85

    Google Scholar 

  20. Pearce N, Grainger J, Atkinson M, et al (1990) Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977–1981. Thorax 45: 170–5

    Article  PubMed  CAS  Google Scholar 

  21. Grainger J, Woodman K, Pearce N, et al (1991) Prescribed fenoterol and death from asthma in New Zealand, 1981–1987: a further case control study. Thorax 46: 105–11

    Article  PubMed  CAS  Google Scholar 

  22. Pearce N, Beasley R, Crane J, et al (1995) End of the New Zealand asthma mortality epidemic. Lancet 345: 41–4

    Article  PubMed  CAS  Google Scholar 

  23. Beasley R, Burgess C, Crane J, et al (1995) The New Zealand asthma mortality epidemic. Clin Sci 88: 14–7

    PubMed  CAS  Google Scholar 

  24. Suissa S, Blais L, Ernst P (1994) Patterns of increasing (3-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 7: 1602–9

    Article  PubMed  CAS  Google Scholar 

  25. Mullen M, Mullen B, Carey M (1993) The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA 270: 1842–5

    Article  PubMed  CAS  Google Scholar 

  26. Cheung D, Timmers MC, Zwinderman AH, et al (1992) The prolonged effects of a long-acting (32-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327: 1198–203

    Article  PubMed  CAS  Google Scholar 

  27. Booth H, Fishwick K, Harkawat R, et al (1993) Changes in methacholine induced bronchoconstriction with the long acting beta2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 48: 1121–4

    Article  PubMed  CAS  Google Scholar 

  28. Giannini D, Carletti A, Dente FL, et al (1995) Tolerance to salmeterol in allergen induced bronchoconstriction. Am J Resp Crit Care Med 151: A39

    Google Scholar 

  29. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP (1994) Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Resp Med 88: 363–8

    Article  CAS  Google Scholar 

  30. Ramage L. Beta2-adrenergic agonists in asthma. MD Thesis, University of Aberdeen, UK (submitted)

    Google Scholar 

  31. Castle W, Fuller R, Hull J, et al (1993) The Serevent nationwide surveillance study. Brit Med J 306: 1034–7

    Article  PubMed  CAS  Google Scholar 

  32. Devoy MAB, Fuller RW, Palmer JBD (1995) Are there any detrimental effects of the use of inhaled long-acting β2-agonists in the treatment of asthma. Chest 107: 1116–24

    Article  PubMed  CAS  Google Scholar 

  33. Britton MG, Earnshaw JS, Palmer JBD (1992) A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 5: 1062–7

    PubMed  CAS  Google Scholar 

  34. Lundback B, Rawlinson DW, Palmer JBD (1993) Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 48: 148–53

    Article  PubMed  CAS  Google Scholar 

  35. Pearlman DS, Chervinsky P, LaForce C, et al (1992) A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 327: 1420–5

    Article  PubMed  CAS  Google Scholar 

  36. D’Alonzo GE, Nathan RA, Henochowicz S, et al (1994) Salmeterol xinofoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 271: 1412–6

    Article  PubMed  Google Scholar 

  37. Dahl R, Earnshaw JS, Palmer JB (1991) Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 4: 1178–84

    PubMed  CAS  Google Scholar 

  38. Britton MG, Earnshaw JS, Palmer JB (1992) A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 5: 1062–67

    PubMed  CAS  Google Scholar 

  39. Fitzpatrick MF, MacKay T, Driver H, Douglas NJ (1990) Salmeterol in nocturnal asthma: a double-blind, placebo controlled trial of long-acting inhaled (β2-agonist. Br Med J 301: 1365–68

    Article  CAS  Google Scholar 

  40. Muir JF, Bertin L, Georges D (1992) Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. Eur Respir J 5: 1197–1200

    PubMed  CAS  Google Scholar 

  41. Fjellbirkeland L, Gulsvik A, Palmer JBD (1994) The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 88: 599–607

    Article  PubMed  CAS  Google Scholar 

  42. Matusiewicz SP, Dewar M, Howie SEM, Grenning AP (1993) Salmeterol therapy for severe nocturnal asthma does not influence blood lymphocyte and monocyte cell surface activation. Am Rev Respir Dis 147: A980

    Google Scholar 

  43. Green CP, Price JF (1992) Prevention of exercise induced asthma by inhaled salmeterol xinofoate. Arch Dis Child 67: 1014–17

    Article  PubMed  CAS  Google Scholar 

  44. Kemp JP, Dockhorn RJ, Busse WW, Bleeker ER, van As A (1994) Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Resp Crit Care Med 150: 1612–1615

    PubMed  CAS  Google Scholar 

  45. International consensus report on the diagnosis and management of asthma (1992) Clin Exp Allergy 22 [Suppl]: 1–72

    Google Scholar 

  46. Guidelines on the management of asthma (1993) Thorax 48 [Suppl]: S 1–24

    Article  Google Scholar 

  47. Workshop: Pharmacological treatments of bronchial asthma II. (1993) 178–9. Läkemedelsverket, Medical Products Agency, Uppsala, Sweden

    Google Scholar 

  48. Toogood JH, Lefcoe NM, Haines DSM, et al (1977) A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 59: 298–308

    Article  PubMed  CAS  Google Scholar 

  49. Gaddie J, Petrie GR, Reid IW, et al (1973) Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma. Lancet ii: 280–81

    Article  Google Scholar 

  50. Hummel S, Lehtonen L and Study Group (1992) Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma. Lancet 340: 1483–87

    Article  Google Scholar 

  51. Sears MR, Taylor DR, Print CG, et al (1992) Increased inhaled bronchodilator vs increased inhaled corticosteroid in the control of moderate asthma. Chest 102: 1709–15

    Article  PubMed  CAS  Google Scholar 

  52. Greening AP, Ind PW, Northfield M, et al (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344: 219–24

    Article  PubMed  CAS  Google Scholar 

  53. Woolcock A, Lundback B, Ringdal N, Jacques LA (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153: 1481–88

    PubMed  CAS  Google Scholar 

  54. Tattersfield AE, Wilding P, Thompson-Coon J, et al (1996) Efficacy and safety of long term treatment with salmeterol in adults with asthma. Am J Respir Crit Care Med 153: A66

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Respiratory Medicine Clinic, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK

    Dr. Andrew P. Greening (Consultant Physician)

Authors
  1. Dr. Andrew P. Greening
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 2. Medizinische Abteilung mit Lungenkrankheiten und Tuberkulose, Wilhelminenspital, Wien, Österreich

    Friedrich Kummer

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag/Wien

About this paper

Cite this paper

Greening, A.P. (1998). Salmeterol and its relationship to treatment with inhaled corticosteroids. In: Kummer, F. (eds) Treatment of Asthma: The long-acting beta-2-agonists. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7513-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-7513-2_9

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83124-3

  • Online ISBN: 978-3-7091-7513-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation